FDA DrugClass II

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10.

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit…

From the FDA notice · Read the official notice ↗

What to do

The agency's notice has the remedy and who to contact.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10.
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 2 products — see all of them.

Details

Units affected
3397 bottles
Illnesses reported
None reported
Manufactured in
200 Connell Dr Ste 4200, Berkeley Heights, NJ, United States
Classification
Class II
Recall number
D-0215-2026

In the FDA's words

Description
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10. CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit Lot #: 240947C, 240962C, Exp. Date 04/2027 Distribution: Nationwide within the United States Affected quantity: 3397 bottles
Hazard
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

2 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

Industrial chemicalsDrugsSold nationwideMore from FDA Drug